Featured Content

ASCO Advance of the Year: Immunotherapy 2.0

The American Society of Clinical Oncology (ASCO) named Immunotherapy 2.0 the "advance of the year."

Smoking Cessation After Diagnosis: A Consistent Survival Benefit

Smoking cessation may improve survival regardless of the type of cancer diagnosed, due to a reduction in comorbidities.

Do Clinical Trials Overstate New Cancer Drugs' Survival Benefits?

Experts disagree about whether success in clinical trials translates to success in real world treatment settings.

The 21st Century Cures Act: An Unclear Advance

Critics worry that changes to the FDA's drug approval process could lead to increased off-label prescribing and the marketing of questionable therapies.

ERCC1: Signals of Needed Research

Challenges persist in identifying predictive biomarkers for targeted chemotherapy, but new technologies offer potential.

Video Series

Featured Slideshow

Targeted Therapy for Patients With Lung Cancer

Factors that affect survival, genetic mutations, and more.

Lung Cancer Resources

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters